Abel Alfonso, DO
Endocrinology, Diabetes & Metabolism · Mankato, MNNPI 1174617740
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,076 of the $1,576 with a category attached, or 68.3%. 20 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 34.5% of the total. Reporting peaked in 2020 at $522 and has fallen 89.7% since, to $54 in 2025.
Across 54 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$544
- Dexcom, Inc.$314
- Novo Nordisk$175
- Lilly USA, LLC$122
- Medtronic$77
- Insulet Corporation$56
- plus $289 from 14 others
What the payments were for
- Speaking & faculty fees$50032%
- Food & beverage$1,07668%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 5 | $544 |
| Dexcom, Inc. | 9 | $314 |
| Novo Nordisk | 5 | $175 |
| Lilly USA, LLC | 8 | $122 |
| Medtronic(2 entities) | 5 | $77 |
| Insulet Corporation | 4 | $56 |
| Ascendis Pharma Endocrinology Inc | 3 | $50 |
| Senseonics, Incorporated | 2 | $37 |
| AstraZeneca | 1 | $24 |
| Corcept Therapeutics | 1 | $21 |
| BETA Bionics, Inc. | 2 | $21 |
| Intuity Medical Inc | 1 | $18 |
| Cequr Corporation | 1 | $17 |
| Abbott | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Companion Medical, Inc. | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,576 in reported general payments places this provider in the 60th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $113,944 |
| MounjaroTirzepatide | 41 | $57,810 |
| ForteoTeriparatide | 13 | $52,273 |
| JardianceEmpagliflozin | 32 | $29,627 |
| TrulicityDulaglutide | 15 | $27,797 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $18,098 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $15,033 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $14,971 |
| FarxigaDapagliflozin Propanediol | 13 | $14,658 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $12,838 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $6,321 |
| Novolog FlexpenInsulin Aspart | 28 | $5,719 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $5,025 |
| SynthroidLevothyroxine Sodium | 29 | $1,997 |
| Levothyroxine Sodium | 88 | $1,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $122 | $137,88069 claims |
| Novo NordiskOzempic | $175 | $113,94487 claims |
| AstraZenecaFarxiga | $24 | $14,65813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Mankato
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
- Sidney JonesChaska$67K
- Maria CastroRochester$63K
- Marius StanRochester$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.